Biomedicine & Pharmacotherapy,
Journal Year:
2022,
Volume and Issue:
157, P. 113977 - 113977
Published: Nov. 7, 2022
COVID-19
is
a
worldwide
pandemic
caused
by
SARS-coronavirus-2
(SARS-CoV-2).
Less
than
year
after
the
emergence
of
Covid-19
pandemic,
many
vaccines
have
arrived
on
market
with
innovative
technologies
in
field
vaccinology.
Based
use
messenger
RNA
(mRNA)
encoding
Spike
SARS-Cov-2
protein
or
recombinant
adenovirus
vectors
enabling
gene
to
be
introduced
into
our
cells,
these
strategies
make
it
possible
envisage
vaccination
new
light
tools
that
are
more
scalable
vaccine
used
so
far.
Faced
appearance
variants,
which
will
gradually
take
precedence
over
strain
at
origin
allow
much
faster
update
fight
against
some
may
escape
neutralization
antibodies.
However,
only
policy
based
rapid
and
massive
population
but
requiring
supply
sufficient
doses
could
combat
variants.
Indeed,
greater
number
infected
individuals,
virus
multiplies,
an
increased
risk
variants
viruses.
This
review
discuss
SARS-CoV-2
pathophysiology
evolution
approaches
altered
transmission
platforms
emphasize
different
mutations
how
they
influence
characteristics.
Also,
this
article
summarizes
common
implication
genetic
variety
biomedical
arbitrations.
JAMA Network Open,
Journal Year:
2022,
Volume and Issue:
5(9), P. e2231778 - e2231778
Published: Sept. 15, 2022
The
BNT162b2
two-dose
vaccine
(BioNTech/Pfizer)
has
high
effectiveness
that
wanes
within
several
months.
third
dose
is
effective
in
mounting
a
significant
immune
response,
but
its
durability
unknown.To
compare
antibody
waning
after
second
and
doses
estimate
the
association
of
kinetics
with
susceptibility
to
infection
Omicron
variant
SARS-CoV-2.In
prospective
longitudinal
cohort
study
tertiary
medical
center
Israel,
health
care
workers
who
received
were
followed
up
monthly
for
IgG
neutralizing
levels.
Linear
mixed
models
used
titer
assess
whether
dynamics
associated
transmission.
Avidity,
T
cell
activation,
microneutralization
sera
against
different
variants
concern
assessed
subgroup.Vaccination
booster
vaccine.The
primary
outcome
was
rate
change
over
time,
secondary
SARS-CoV-2
infection,
as
confirmed
by
reverse
transcriptase-polymerase
chain
reaction.Overall,
4868
(mean
[SD]
age,
46.9
[13.7]
years;
3558
[73.1%]
women)
3972
48.5
[14.1]
996
[74.9%]
5
months
their
doses,
respectively.
Waning
levels
slower
compared
(1.32%/d
[95%
CI,
1,29%/d
1.36%/d]
vs
2.26%
2.13%/d
2.38%/d]),
1.21%/d
1.43%/d]
3.34%/d
3.11%/d
3.58%/d]).
Among
2865
incidence
during
an
additional
2
follow-up,
lower
peak
(ratio
means
0.86
0.80-0.91])
among
participants
aged
65
years
older,
faster
antibodies
mean
rates,
1.40;
1.13-1.68]
3.58
1.92-6.67],
respectively)
infection.
No
avidity
observed
112
days
dose.
Live
neutralization
previous
strains,
geometric
at
111
(95%
75-166),
942
585-1518)
WT,
410
266-634)
Delta;
it
demonstrated
similar
26
16-42)
4
77
tested
activity,
(SD)
activity
decreased
from
98
(5.4)
cells/106
peripheral
blood
mononuclear
cells
59
(9.3)
cells.This
found
greater
than
dose;
however,
resistance
wild
type
Delta
concern.
Humoral
response
Science Immunology,
Journal Year:
2022,
Volume and Issue:
7(70)
Published: Feb. 3, 2022
Multiple
SARS-CoV-2
variants
have
mutations
in
the
spike
receptor
binding
domain
(RBD)
with
potential
to
evade
neutralizing
antibody.
In
particular,
Beta
and
Omicron
escape
from
antibody
activity
those
who
received
two
doses
of
BNT162b2
mRNA
vaccine.
Nonetheless,
boosting
a
third
vaccine
dose
or
by
breakthrough
infection
improves
overall
breadth
antibodies,
but
mechanism
remains
unclear.
Here,
we
longitudinally
profiled
cellular
composition
RBD-binding
memory
B
cell
subsets
their
against
after
second
Two
elicited
plasma
antibodies
limited
induced
an
expanded
overtime,
up
4.9
months
vaccination.
contrast,
more
than
one-third
IgG+
cells
resting
phenotype
initially
bound
steadily
increased
overtime.
As
result,
fraction
subset
secreted
Omicron-neutralizing
when
stimulated
vitro.
The
helps
us
understand
prominent
recall
additional
booster
fully
vaccinated
individuals.
Biomedicine & Pharmacotherapy,
Journal Year:
2022,
Volume and Issue:
154, P. 113522 - 113522
Published: Aug. 15, 2022
Since
the
start
of
COVID-19
pandemic,
numerous
variants
SARS-CoV-2
have
been
reported
worldwide.
The
advent
concern
(VOCs)
raises
severe
concerns
amid
serious
containment
efforts
against
that
include
physical
measures,
pharmacological
repurposing,
immunization,
and
genomic/community
surveillance.
Omicron
variant
(B.1.1.529)
has
identified
as
a
highly
modified,
contagious,
crucial
among
five
VOCs
SARS-CoV-2.
increased
affinity
spike
protein
(S-protein),
host
receptor,
angiotensin
converting
enzyme-2
(ACE-2),
due
to
higher
number
mutations
in
receptor-binding
domain
(RBD)
S-protein
proposed
primary
reason
for
decreased
efficacy
majorly
available
vaccines
transmissible
nature
variant.
Because
its
significant
competitive
advantage,
sublineages
swiftly
surpassed
other
become
dominant
circulating
lineages
nations.
prevalent
strain
United
Kingdom
South
Africa.
Furthermore,
emergence
recombinant
through
conjunction
with
or
by
mixing
variant's
sublineages/subvariants
poses
major
threat
humanity.
This
various
issues
hazards
regarding
sublineages,
such
an
breakout
susceptible
populations
fully
vaccinated
persons.
As
result,
understanding
features
genetic
implications
this
is
crucial.
Hence,
we
explained
depth
evolution
analyzed
repercussions
on
infectiousness,
dissemination
ability,
viral
entry
mechanism,
immune
evasion.
We
also
presented
viewpoint
feasible
strategies
precluding
counteracting
any
future
catastrophic
spread
omicron
could
result
detrimental
wave
cases.
PLoS Medicine,
Journal Year:
2022,
Volume and Issue:
19(5), P. e1003991 - e1003991
Published: May 17, 2022
Emerging
and
future
SARS-CoV-2
variants
may
jeopardize
the
effectiveness
of
vaccination
campaigns.
Therefore,
it
is
important
to
know
how
different
vaccines
perform
against
diverse
variants.
Biomedicine & Pharmacotherapy,
Journal Year:
2022,
Volume and Issue:
157, P. 113977 - 113977
Published: Nov. 7, 2022
COVID-19
is
a
worldwide
pandemic
caused
by
SARS-coronavirus-2
(SARS-CoV-2).
Less
than
year
after
the
emergence
of
Covid-19
pandemic,
many
vaccines
have
arrived
on
market
with
innovative
technologies
in
field
vaccinology.
Based
use
messenger
RNA
(mRNA)
encoding
Spike
SARS-Cov-2
protein
or
recombinant
adenovirus
vectors
enabling
gene
to
be
introduced
into
our
cells,
these
strategies
make
it
possible
envisage
vaccination
new
light
tools
that
are
more
scalable
vaccine
used
so
far.
Faced
appearance
variants,
which
will
gradually
take
precedence
over
strain
at
origin
allow
much
faster
update
fight
against
some
may
escape
neutralization
antibodies.
However,
only
policy
based
rapid
and
massive
population
but
requiring
supply
sufficient
doses
could
combat
variants.
Indeed,
greater
number
infected
individuals,
virus
multiplies,
an
increased
risk
variants
viruses.
This
review
discuss
SARS-CoV-2
pathophysiology
evolution
approaches
altered
transmission
platforms
emphasize
different
mutations
how
they
influence
characteristics.
Also,
this
article
summarizes
common
implication
genetic
variety
biomedical
arbitrations.